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372Objective: Although lobectomy is the standard surgical procedure for operable non–small cell lung cancer
(NSCLC), sublobar resection also has been undertaken for various reasons. The aim of this study was to identify
risk factors of locoregional recurrence and poor disease-specific survival in patients with clinical stage IA
NSCLC undergoing sublobar resection.
Methods:We retrospectively reviewed 328 patients with clinical stage IANSCLCwho underwent segmentectomy
orwedge resection.Demographic, clinical, andpathologic factorswere analyzedusing the log-rank test as univariate
analyses, and all factors were entered into a Cox proportional hazards regressionmodel for multivariate analyses to
identify independent predictors of locoregional recurrence and poor disease-specific survival.
Results: The 5- and 10-year locoregional recurrence–free probabilities were 84.8% and 83.6%, respectively,
and the 5- and 10-year disease-specific survivals were 83.6% and 73.6%, respectively. Four independent
predictors of locoregional recurrence were identified: wedge resection (hazard ratio [HR], 5.787), microscopic
positive surgical margin (HR, 3.888), visceral pleural invasion (HR, 2.272), and lymphatic permeation
(HR, 3.824). Independent predictors of poor disease-specific survival were identified as follows: smoking status
(Brinkman Index; HR, 1.001), wedge resection (HR, 3.183), microscopic positive surgical margin (HR, 3.211),
visceral pleural invasion (HR, 2.553), and lymphatic permeation (HR, 3.223). All 4 predictors of locoregional
recurrence also were identified as independent predictors of poor disease-specific survival.
Conclusions: Segmentectomy should be the surgical procedure of first choice in patients with clinical stage IA
NSCLC who are being considered for sublobar resection. Patients having tumors presenting with no suspicious
of pleural involvement would be suitable candidates for sublobar resection. (J Thorac Cardiovasc Surg
2013;146:372-8)Earn CME credits at
http://cme.ctsnetjournals.org
Ever since the LungCancer StudyGroup (LCSG) performed
a prospective and randomized study of limited resection ver-
sus lobectomy in patients with peripheral T1 lung cancers
and reported the results of the study in 1995,1 lobectomy
has been the standard surgical procedure for early-stage
non–small cell lung cancer (NSCLC). The LCSG reported
an approximately 3-fold increase of the locoregional recur-
rence rate in patients who underwent limited resection com-
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The Journal of Thoracic and Cardiovascular SurgHowever, sublobar resection, such as segmentectomy and
wedge resection, could benefit patients with NSCLC with
comorbid disease or decreased pulmonary function,2 or
older patients with a limited life expectancy.3 Moreover,
several prospective trials of intentional sublobar resection
for small peripheral NSCLC in patients with adequate pul-
monary function for lobectomy have been conducted re-
cently,4,5 on the basis of the evidence that smaller lesions
are likely to represent an earlier stage and potentially
more liable to cure.6 Furthermore, favorable outcomes
of sublobar resection have been reported in patients
with NSCLC with a relatively high percent area of
ground-glass opacity on computed tomography (CT),7,8
which is considered to be indicative of less invasive
adenocarcinoma. Despite the reported equivalent survival
between patients undergoing intentional sublobar resection
and lobectomy, a suitable population for sublobar
resection with a low risk of locoregional recurrence has
still not been established.
In the current study, we retrospectively reviewed the data
of patients with clinical stage IA NSCLC who underwent
segmentectomy or wedge resection at the Niigata Cancer
Center Hospital in an attempt to identify the independent
demographic, clinical, and pathologic predictors of locore-
gional recurrence and poor disease-specific survival.ery c August 2013
Abbreviations and Acronyms
BI ¼ Brinkman Index
CEA ¼ carcinoembryonic antigen
CI ¼ confidence interval
Cons/Tumor ratio ¼ consolidation/tumor ratio
CT ¼ computed tomography
HR ¼ hazard ratio
LCSG ¼ Lung Cancer Study Group
NSCLC ¼ non–small cell lung cancer
PET ¼ positron emission tomography
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SMATERIALS AND METHODS
Patients
This study was approved by the institutional review board of the Niigata
Cancer Center Hospital. Because this was a retrospective study, the need to
obtain written informed consent from each patient was waived.
In this study, we conducted a retrospective evaluation of patients with
clinical stage IA NSCLC, according to the 7th edition of the TNM classi-
fication,9 who had undergone segmentectomy or wedge resection at the
Niigata Cancer Center Hospital, Niigata, Japan. Patients meeting the fol-
lowing criteria were excluded: with a nonperipherally located carcinoma
visualized by bronchoscopy, evidence of multiple lung carcinomas, evi-
dence of pleural dissemination, positive pleural effusion or lavage cytol-
ogy, and planned adjuvant therapy after surgical resection (Figure 1).
Patients with pathologically diagnosed adenocarcinoma in situ also were
excluded, because this is a preinvasive state of adenocarcinoma, and
locoregional recurrence is not expected to develop even after sublobar
resection.7,8
A total of 328 patients with clinical stage IA NSCLC treated between
January 1998 and December 2009 fulfilled the inclusion criteria for this
study and were enrolled. Of the eligible patients, 196 were male and 132
were female, and the median age was 71 years (range, 42-89 years;
Table 1). All the patients had clinical stage IA disease, and 80 of the 328
patients (24.4%) had clinical T1b disease. Segmentectomy was performed
in 216 patients (65.9%), and wedge resection was performed in 112 pa-
tients (34.1%); systematic mediastinal lymphadenectomy was performed
in 86 patients (26.2%). Tumor histology was adenocarcinoma in 269 pa-
tients (82.0%), squamous cell carcinoma in 46 patients (14.0%), and other
cell types in 13 patients (4.0%).
Preoperative Evaluation
All patients underwent preoperative staging with CT and pulmonary
function testing. Additional diagnostic testing (brain magnetic resonance
imaging and bone scintigraphy) was performed at the discretion of the
individual physician, according to the patient’s symptoms and clinical
findings. Because positron emission tomography (PET) combined with
CT was introduced at the Niigata Cancer Center Hospital in 2010,
PET-CT was not used for preoperative staging in any of the patients en-
rolled in this study. No invasive modalities for mediastinal lymph node
staging, such as mediastinoscopy or endobronchial ultrasound-guided
transbronchial needle aspiration, were used preoperatively in any of
these patients.
Surgery
Sublobar resection is selected for the treatment of high-risk subgroup of
patients with decreased pulmonary function or comorbid disease, such as
previous treatment for other malignancies, underlying pulmonary disease,
underlying heart disease, and advanced age. In patients with tumorsThe Journal of Thoracic and Capresenting with a low consolidation/tumor (Cons/Tumor) ratio on CT
(a maximum diameter of consolidation divided by the maximum tumor di-
ameter on CT),10 intentional segmentectomy or wedge resection was
performed, and the extent of pulmonary resection was determined
depending on the tumor size and location. Intentional segmentectomy
also was performed in patients with cT1a with adequate pulmonary func-
tion.4 In these patients, intraoperative surgical margin lavage cytology
was performed in patients in whom the tumor was close to the surgical mar-
gin, and negative cytology was confirmed. In some intentionally indicated
patients, the N1 nodes were pathologically assessed intraoperatively, and if
positive, the surgical procedure was converted to lobectomy. In patients at
high risk for lobectomy or who underwent wedge resection, the intraoper-
ative pathologic N1 node assessment was performed only when a positive
N1 node was strongly suggested by intraoperative findings.
Postoperative Follow-up
According to the hospital’s clinical routine of postoperative follow-
up, postoperative patients were seen approximately every 3 months after
sublobar resection, and the follow-up evaluation included physical exam-
ination, chest radiography, and blood examination including measure-
ments of tumor markers. A CT scan of the thorax was performed
every year for the first 5 years post-resection and then as necessary after
the first 5 years post-resection. If the patient showed any symptoms or
signs of recurrence, further evaluations were performed, including CT,
brain magnetic resonance imaging, and bone scintigraphy. Since 2010,
we have performed PET-CT when necessary. Recurrence was defined
as locoregional if it occurred within the same lobe, or in the ipsilateral
thoracic cavity, and hilum or mediastinal lymph nodes. Newly developed
lung lesions only in the same lobe were scored as local recurrence unless
the lesions showed different histologic subtypes from a primary lung
carcinoma.
Data
We reviewed the medical records of each patient to obtain data, includ-
ing age (71 years or>71 years), gender, smoking status (Brinkman In-
dex [BI],11 0,>0-600, or>600), preoperative serum carcinoembryonic
antigen (CEA) level (<5 ng/mL or 5 ng/mL), tumor location (right up-
per or middle, right lower, left upper, or left lower lobe), tumor size on
preoperative radiologic imaging (2.0 or 2.1-3.0 cm), Cons/Tumor ratio
on CT10 (75% or>75%), reason for sublobar resection (compromised
or intentional), extent of pulmonary resection (segmentectomy or wedge
resection), extent of lymphadenectomy (sampling only or systematic
mediastinal lymphadenectomy), tumor histology (adenocarcinoma, squa-
mous cell carcinoma, or other cell types), tumor size in the resected lung
specimens (2.0, 2.1-3.0, or 3.1-5.0 cm), microscopic surgical margin
(negative or positive), pathologically diagnosed lymph node metastasis
(absent or present), visceral pleural invasion (absent or present), lym-
phatic permeation (absent or present), and vascular invasion (absent or
present).
For the univariate analysis to determine the influence of age, the pa-
tients were divided into 2 groups by the median age of 71 years. The BI
was scored as the number of cigarettes smoked per day multiplied by
the number of years smoked.11 The cutoff point of the BI was set at 600
on the basis of a previous report,12 and a BI greater than 600 indicated
heavy smoking. The cutoff for the normal upper limit of serum CEA
was set at 5 ng/mL. The Cons/Tumor ratio was defined as the maximum
diameter of consolidation divided by the maximum tumor diameter on
CT10 and evaluated with the reconstructed thin-section helical CT scan.
The patients were divided into 2 groups by 75% of Cons/Tumor ratio as
used in a previous report,13 and a high Cons/Tumor ratio indicated an ag-
gressive disease in the report. Presence or absence of visceral pleural inva-
sion, lymphatic permeation, and vascular invasion were evaluated by
pathologists in specimens stained with hematoxylin–eosin and Elastica
van Gieson stain.rdiovascular Surgery c Volume 146, Number 2 373
FIGURE 1. CONSORT-style diagram illustrating the selection of patients
included in the data analysis. NSCLC, Non–small cell lung cancer.
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The locoregional recurrence-free probability was measured from the
date of surgery to the date of detection of the first locoregional recurrence
or the date of last follow-up. Locoregional recurrence was scored only
when it was identified as the first recurrence site. The length of disease-
specific survival was estimated as the interval from the date of surgery to
the date of a specific cause of death or the date of last follow-up. For the
univariate analyses, the locoregional recurrence-free probability and
disease-specific survival were calculated using the Kaplan–Meier method,
and predictors of locoregional recurrence and poor disease-specific sur-
vival were analyzed with the log-rank test. The Bonferroni correction for
multiple comparisons was used for each individual comparison. The di-
chotomized data were used only for the univariate analysis in each contin-
uous variable (age, BI, preoperative serum CEA level, tumor size on
preoperative radiologic imaging, Cons/Tumor ratio on CT, and tumor
size in the resected lung specimens). All factors were entered into a Cox
proportional regression hazard model for multivariate analysis. In the mul-
tivariate analysis, categoric variables (sex, tumor location, reason for sub-
lobar resection, pulmonary resection extent, lymphadenectomy extent,
tumor histology, microscopic surgical margin, lymph nodemetastasis, lym-
phatic permeation, and vascular invasion) and continuous variables (age
[years], BI, preoperative serum CEA level [nanograms/milliliter], tumor
size on preoperative radiologic imaging [centimeters], Cons/Tumor ratio
on CT [percent], and tumor size in the resected lung specimens [centime-
ter]) were assessed to identify independent predictors. A stepwise selection
method was used to identify the risk factors of locoregional recurrence and
independent prognostic factors. The assumption of proportionality in each
significant variable was verified using log-minus-log survival plots. All
analyses were performed using IBM SPSS 20.0 (IBM Co, Chicago, Ill).RESULTS
During the follow-up period, locoregional recurrence de-
veloped in 51 patients, represented by pulmonary metasta-
sis in the same lobe in 34 cases, metastasis in the
intrathoracic lymph nodes in 12 cases, pleural dissemina-
tion in 2 cases, and both pulmonary metastasis in the374 The Journal of Thoracic and Cardiovascular Surgsame lobe and metastasis in the intrathoracic lymph nodes
in 3 cases. In the 15 patients in whom intrathoracic lymph
node metastases developed, 3 underwent mediastinal lym-
phadenectomy (data not shown). The 5- and 10-year locore-
gional recurrence-free probabilities were 84.8% and
78.2%, respectively, with a median follow-up period of
58 months (range, 2-162 months; Figure 2, A). The 5- and
10-year disease-specific survivals were 83.6% and
73.6%, respectively, with a median follow-up period of
62 months (range, 3-170 months; Figure 2, B).
The univariate analyses identified the following signifi-
cant factors of a reduced locoregional recurrence-free prob-
ability: age greater than 71 years, male gender, BI greater
than 600, serum CEA 5 ng/mL or greater, radiologic tumor
size 2.1 to 3.0 cm, Cons/Tumor ratio on CT greater than
75%, indication for compromised patients, wedge resec-
tion, lymph node sampling only, squamous cell carcinoma,
microscopic positive surgical margin, lymph node metasta-
sis, visceral pleural invasion, lymphatic permeation, and
vascular invasion (Table 1). For disease-specific survival,
the following were identified as significant factors in the
univariate analyses: age greater than 71 years, male gender,
BI greater than 600, serum CEA 5 ng/mL or greater, radio-
logic tumor size 2.1 to 3.0 cm, Cons/Tumor ratio on CT
greater than 75%, indication for compromised patients,
wedge resection, squamous cell carcinoma, positive micro-
scopic surgical margin, lymph node metastasis, visceral
pleural invasion, lymphatic permeation, and vascular inva-
sion (Table 1).
A multivariate analysis using the Cox proportional haz-
ards regression model revealed the following 4 significant
independent predictors of locoregional recurrence: wedge
resection (hazard ratio [HR], 5.787; 95% confidence inter-
val [CI], 3.018-11.098, P<.001), microscopic positive sur-
gical margin (HR, 3.888; 95% CI, 1.634-9.255; P ¼ .002),
visceral pleural invasion (HR, 2.272; 95% CI, 1.282-4.027;
P ¼ .005), and lymphatic permeation (HR, 3.824; 95% CI,
2.028-7.210; P<.001; Table 2). In addition, the following
were identified as the factors associated with a poor
disease-specific survival: smoking status (BI; HR, 1.001;
95% CI, 1.000-1.001; P ¼ .003), wedge resection
(HR, 3.183; 95% CI, 1.756-5.771; P<.001), microscopic
positive surgical margin (HR, 3.211; 95% CI, 1.427-
7.255; P ¼ .005), visceral pleural invasion (HR, 2.553;
95%CI, 1.503-4.388; P¼ .001), and lymphatic permeation
(HR, 3.223; 95% CI, 1.773-5.860; P < .001; Table 2).
Among the 4 independent predictors of locoregional recur-
rence identified, all 4 factors also were identified as
independent predictors of poor disease-specific survival.
DISCUSSION
In the present study, we retrospectively reviewed the
data of 328 patients with clinical stage IA NSCLC who
underwent sublobar resection in an attempt to identifyery c August 2013
TABLE 1. Demographic, clinical, and pathologic characteristics, and univariate analysis of locoregional recurrence-free probability and disease-
specific survival for 328 patients with clinical stage IA non–small cell lung cancer undergoing sublobar resection
Variable No. of patients (%)
5-y locoregional recurrence-free
probability (%)
Univariate
P value
5-y disease-specific
survival (%)
Univariate
P value
All cases 328 (100) 84.8 83.6
Age
71 y 177 (54) 90.1 89.8
>71 y 151 (46) 78.5 .001{ 76.6 .001{
Sex
Male 196 (60) 78.2 77.6
Female 132 (40) 93.6 .001{ 88.6 .007{
Smoking status (BI*)
0 138 (42) 92.4 92.0
>0-600 33 (10) 93.4 83.2
>600 157 (48)x 75.5 .002{ 76.1 .003{
CEAy
Within normal range 277 (84) 88.6 88.6
Elevated 51 (16) 63.1 <.001{ 57.1 <.001{
Tumor location
Right upper or middle lobe 113 (35) 86.2 82.5
Right lower lobe 69 (21) 81.7 82.2
Left upper lobe 89 (27) 90.1 87.9
Left lower lobe 57 (17) 76.6 .264 81.0 .764
Tumor size, radiologic
2.0 cm 248 (76) 88.8 88.3
2.1-3.0 cm 80 (24) 72.1 <.001{ 69.1 .001{
Cons/Tumor ratioz
75% 89 (27) 96.5 97.5
>75% 239 (63) 80.5 <.001{ 78.7 <.001{
Reason for sublobar resection
Compromised 160 (49) 74.8 79.3
Intentional 168 (51) 93.5 <.001{ 93.0 <.001{
Pulmonary resection extent
Segmentectomy 216 (66) 93.7 91.3
Wedge resection 112 (34) 66.0 <.001{ 68.0 <.001{
Lymphadenectomy extent
Sampling only 242 (74) 82.7 81.4
Systematic mediastinal node dissection 86 (26) 91.0 .040{ 90.1 .095
Tumor histology
Adenocarcinoma 269 (82) 88.5 86.6
Squamous cell carcinoma 46 (14)k 62.6 72.4
Others 13 (4) 61.5 .002{ 61.5 .007{
Tumor size, pathologic
2.0 cm 246 (75) 86.9 85.4
2.1-3.0 cm 64 (20) 76.0 73.5
3.1-5.0 cm 18 (5) 87.2 .131 94.4 .112
Microscopic surgical margin
Positive 11 (3) 24.2 18.2
Negative 317 (97) 86.9 <.001{ 85.9 <.001{
Lymph node metastasis
Absent 318 (97) 86.3 84.4
Present 10 (3) 40.0 <.001{ 60.0 .002{
Visceral pleural invasion
Absent 260 (79) 89.0 88.9
Present 68 (21) 68.5 <.001{ 65.1 <.001{
(Continued)
Koike et al General Thoracic Surgery
The Journal of Thoracic and Cardiovascular Surgery c Volume 146, Number 2 375
G
T
S
TABLE 1. Continued
Variable No. of patients (%)
5-y locoregional recurrence-free
probability (%)
Univariate
P value
5-y disease-specific
survival (%)
Univariate
P value
Lymphatic permeation
Absent 278 (85) 88.2 86.6
Present 50 (15) 65.4 <.001{ 66.7 <.001{
Vascular invasion
Absent 258 (79) 86.3 87.7
Present 70 (21) 71.1 .003{ 68.3 <.001{
BI,Brinkman Index;CEA, carcinoembryonic antigen. *Scored as the number of cigarettes smoked per day multiplied by the number of years since smoking started. yPreoperative
serum CEA level, normal upper limit at 5 ng/mL. zCons/Tumor ratio, consolidation/tumor ratio, a maximum diameter of consolidation divided by the maximum tumor diameter
on CT. xLocoregional recurrence-free probability: 0 versus 600: P ¼ .006; disease-specific survival: 0 versus 600: P ¼ .003. kLocoregional recurrence-free probability:
adenocarcinoma versus squamous cell carcinoma: P ¼ .021; disease-specific survival: adenocarcinoma versus squamous cell carcinoma: P ¼ .027. {Indicates significance.
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disease-specific survival. The multivariate analyses identi-
fied wedge resection, microscopic positive surgical margin,FIGURE 2. Locoregional-free probability (A) and disease-specific sur-
vival curves (B) of the 328 patients with clinical stage IA NSCLC under-
going sublobar resection. A, The 5- and 10-year locoregional-free
probabilities were 84.8% and 78.2%, respectively, over a median
follow-up period of 58 months. B, The 5- and 10-year disease-specific
survivals were 83.6% and 73.6%, respectively, over a median follow-up
period of 62 months.
376 The Journal of Thoracic and Cardiovascular Surgvisceral pleural invasion, and lymphatic permeation as inde-
pendent predictors of locoregional recurrence, and all pre-
dictors also were identified as independent predictors of
poor disease-specific survival.
Lobectomy has been performed as the standard surgical
procedure for operable NSCLC on the basis of the results
of a prospective and randomized study of limited resection
versus lobectomy conducted by the LCSG.1 They reported
an increase of the locoregional recurrence rate after limited
resection even in patients with small NSCLC (3 cm in
size). However, sublobar resection such as segmentectomy
and wedge resection could be indicated in patients with
NSCLC with comorbid disease or decreased pulmonary
function because of its more favorable effect on pulmonary
function preservation14 and the trend toward reduction in
the perioperative morbidity and mortality.15 Moreover, var-
ious studies of intentional sublobar resection for patients
with adequate pulmonary function have been conduct-
ed.4,5,7,8 In the present study, we sought to investigate
patients with clinical stage IA NSCLC who were suitable
for sublobar resection who would be identified by the risk
factors of locoregional recurrence and poor prognosis.
The extent of pulmonary resection was identified as a sig-
nificant independent predictor of both locoregional recur-
rence and poor disease-specific survival. The LCSG
reported a trend toward a higher locoregional recurrence
rate in patients who underwent wedge resection compared
with segmentectomy.1 Many studies demonstrated a signifi-
cantly decreased locoregional recurrence rate and favorable
outcomes after segmentectomy compared with wedge re-
section,6,16 and a similar result also was demonstrated
even in the study that examined matched comparison
groups from a large population-based sample.17 Anatomic
segmentectomy has the theoretic advantages of providing
more comprehensive resection, reduced technical limita-
tions for achieving appropriate margins, and a wider
resection of the draining lymphatics, including interseg-
mental planes, commonly referenced as a source of residual
cancer cells.18 In the current study, microscopic positive
surgical margin on pathologic diagnosis also was found asery c August 2013
TABLE 2. Multivariate Cox proportional hazard analysis of locoregional recurrence-free probability and disease-specific survival for 328 patients
with clinical stage IA non–small cell lung cancer undergoing sublobar resection
Variable
Locoregional recurrence-free probability Disease-specific survival
HR 95% CI P value HR 95% CI P value
Smoking status (BI*) 1.001 1.000-1.001 .003
Pulmonary resection extent
Segmentectomy Reference Reference
Wedge resection 5.787 3.018-11.098 <.001 3.183 1.756-5.771 <.001
Microscopic surgical margin
Positive 3.888 1.634-9.255 .002 3.211 1.427-7.255 .005
Negative Reference Reference
Visceral pleural invasion
Absent Reference Reference
Present 2.272 1.282-4.027 .005 2.553 1.503-4.338 .001
Lymphatic permeation
Absent Reference Reference
Present 3.824 2.028-7.210 <.001 3.223 1.773-5.860 <.001
HR, Hazard ratio; CI, confidence interval; BI, Brinkman Index. *Scored as the number of cigarettes smoked/day multiplied by the number of years since smoking started.
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currence and poor disease-specific survival. Moreover, the
impact of a close surgical margin width on the likelihood
of development of local recurrence has been reported, and
the authors suggested that the frequent association of
wedge resection with a relatively narrower width of the sur-
gical margin was one possible explanation for the higher
risk of locoregional recurrence associated with wedge
resection.16,19 The current study indicates the superior
oncologic outcome of segmentectomy compared with
wedge resection; thus, segmentectomy should be the
surgical procedure of first choice for patients with clinical
stage IA NSCLC being considered for sublobar resection.
In the current study, visceral pleural invasion was defined
as a risk factor for both locoregional recurrence and poor
disease-specific survival. Many previous studies have sug-
gested that visceral pleural invasion is a risk factor for
a poor prognosis in patients with NSCLC,20,21 and tumors
less than 3 cm in diameter with visceral pleural invasion
are upstaged to T2a in the 7th edition of the TNM
classification.9 Although it is difficult to preoperatively di-
agnose visceral pleural invasion on CT, measurement of the
maximum standardized uptake value of the primary tumor
on PET-CT may be a useful marker for predicting pleural
invasion.22
Lymphovascular space invasion, including vascular and
lymphatic invasion, has been reported as one of the inde-
pendent risk factors for local failure in patients with clinical
N0-1 NSCLC undergoing surgical resection.23 In addition,
we previously reported that the lymphatic permeation is the
only independent predictor of both poor prognosis and re-
currence in patients with clinical T1a N0 NSCLC undergo-
ing intentional segmentectomy.13 The present study
revealed that lymphatic permeation is a risk factor for
locoregional recurrence and poor survival in patients withThe Journal of Thoracic and Caclinical stage IA NSCLC treated by sublobar resection.
However, because we can identify the presence of lym-
phatic permeation only in the resected lung specimens,
we cannot preoperatively take this factor into consideration
for determining the indication for sublobar resection. In
cases in which lymphatic permeation is identified on path-
ologic examination of the resected specimen, careful
follow-up is recommended.
The patients with a heavy smoking history showed an un-
favorable prognosis, although the BI was not identified as
an independent predictor for locoregional recurrence. It is
generally accepted that cigarette smoking is the strongest
risk factor for lung cancer.24 In a recent report, existence
of an association between a heavy smoking history and
poor outcomes with histologic tumor invasion of lung ade-
nocarcinoma was demonstrated,21 suggesting that abundant
exposure to cigarette smoke affects the incidence rate of
lung cancer in smokers, as well as the clinical aggressive-
ness of the lung cancer.
Study Limitations
Wemust acknowledge some limitations of this study. Al-
though the extent of pulmonary resection was identified as
a risk factor of locoregional recurrence with a poor progno-
sis, we did not evaluate the impact of the distance from the
margin to the edge of the tumor. Previous studies have
shown the impact of a narrow width of the surgical margin
on the development of local recurrence; thus, the favorable
locoregional control after segmentectomy in the current
study might reflect a relatively large width of the surgical
margin associated with segmentectomy compared with
wedge resection. Moreover, Schuchert and colleagues19
suggested that lobectomy should be considered as primary
therapy when surgical margins are not obtainable with seg-
mentectomy in low-risk patients. Comparative studies withrdiovascular Surgery c Volume 146, Number 2 377
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required to answer this question, best using a randomized
study.
Second, it remains controversial whether our postopera-
tive follow-up protocol of chest radiography every 3 months
and yearly CTwith tumor marker measurements are appro-
priate for the detection of locoregional recurrence. We con-
sidered PET-CT when a pathologic diagnosis could not be
obtained despite identification of a newly developed lung
lesion or when no recurrence lesion was detected by con-
ventional radiologic modalities, such as CT, brain magnetic
resonance imaging, and bone scintigraphy, despite in-
creased tumor markers being identified. PET-CT might be
considered as a routine examination to detect locoregional
recurrence in asymptomatic patients.25
Third, although we evaluated the extent of lymphadenec-
tomy and it was not identified as an independent risk factor
for locoregional recurrence, the number of retrieved
lymph nodes was not assessed despite these data being po-
tentially as important as the extent of lymphadenectomy.20
Moreover, intraoperative lymph node evaluation by frozen-
section examination was performed only in a limited
number of patients; it was rarely performed, especially in
high-risk patients for lobectomy, because conversion of
the surgical procedure to lobectomy was difficult if positive
nodes were identified intraoperatively, and shortening of the
operation time was important. These factors could have ex-
erted an influence on the pathologic lymph node status and
incidence of intrathoracic lymph node recurrence after
resection.
CONCLUSIONS
Wedge resection, microscopic positive surgical margin,
visceral plural invasion, and lymphatic permeation were
identified as independent predictors of locoregional recur-
rence, and all 4 predictors also were identified as indepen-
dent predictors of poor disease-specific survival in
patients with clinical stage IA NSCLC treated by sublobar
resection. Segmentectomy may be useful to achieve nega-
tive surgical margin with an appropriate width of the margin
and should be the surgical procedure of first choice in pa-
tients with clinical stage IA NSCLC being considered for
sublobar resection. Patients having tumors presenting with
no suspicious of pleural involvement would be suitable can-
didates for sublobar resection. Even after sublobar resec-
tion, good local control with a favorable prognosis can be
expected in low-risk patients identified by the risk factors
in the current study.
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